Hamilton Locke advised Cleo Diagnostics Ltd (ASX: COV) on its successful initial public offering and recent listing on the ASX. The IPO raised $12 million for the Victorian based biotech company.
Cleo Diagnostics was incorporated to develop and commercialise three ovarian cancer tests. Cleo Diagnostics is currently the only biotech company listed on the ASX in Australia this year.
The team at Hamilton Locke was led by Partner Jeremy Newman with support from Lawyers James Roberts and Adam Cajaglis. Taylor Collison Limited acted as the lead manager on the transaction.
Click here to read the full ASX announcement.